Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,187 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05634694 | Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients | unknown | — | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER |
| 1 |
| Dec 2, 2022 |
| clinicaltrials |
| NCT04503902 | Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 1 / Phase 2 | 46 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05627297 | Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal Image(AI-HCC) | unknown | — | 200 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT05626127 | MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma | unknown | — | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT05622825 | Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers | unknown | Phase 1 / Phase 2 | 15 | National Taiwan University HospitalOTHER | 0 | Nov 21, 2022 | clinicaltrials |
| NCT05620004 | Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05620498 | Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC. | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05617430 | Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 43 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT05580328 | An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma | unknown | N/A | 10 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Nov 14, 2022 | clinicaltrials |
| NCT05614466 | The SIMPLY-B Study | unknown | N/A | 100 | Nadine BarnesOTHER | 0 | Nov 14, 2022 | clinicaltrials |
| NCT04718909 | Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC(REGSIN) | unknown | Phase 2 | 166 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT05596370 | Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer | unknown | — | 150 | Seoul National University HospitalOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT00986661 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | unknown | Phase 1 | 78 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05603039 | A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 80 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT03641118 | Sarcopenia and Physiology Assessments in Cancer Patients | unknown | — | 639 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05575622 | Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular Carcinoma | unknown | — | 200 | Zhongnan HospitalOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02773485 | Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma | unknown | Phase 3 | 155 | Tata Memorial HospitalOTHER_GOV | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05257694 | Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning | unknown | — | 1 | Ping LiangOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05587556 | Analysis of Clinical Outcomes and Complications in Patients Received Liver Transplantation: A Retrospective Study | unknown | — | 1,400 | China Medical University HospitalOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05350943 | HAIC Combined With Toripalimab and Donafenib for Advanced BTC | unknown | Phase 2 | 70 | Lu Wang, MD, PhDOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05573282 | Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma | unknown | — | 50 | Sun Yat-sen UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05582278 | HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC | unknown | Phase 2 | 60 | Wen LiOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05580224 | Anatomical Radiofrequency Ablation for Small Hepatocellular Carcinoma | unknown | N/A | 87 | Seoul National University HospitalOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05580835 | PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma | unknown | N/A | 100 | University of Sao PauloOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05449873 | No-touch Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Using Triple Cooled-Wet Electrodes | unknown | N/A | 73 | Seoul National University HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05410197 | Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN) | unknown | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05572528 | Lenvatinib Therapy in HCC Patients After LDLT | unknown | — | 30 | Kaoshiung Chang Gung Memorial HospitalOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT03864211 | Thermal Ablation Followed by Immunotherapy for HCC | unknown | Phase 1 / Phase 2 | 145 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05429697 | Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer | unknown | Phase 2 / Phase 3 | 128 | SMT bio Co., Ltd.INDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05555316 | TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma | unknown | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT05550025 | TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer | unknown | Phase 2 | 26 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05545124 | Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence | unknown | Phase 2 | 32 | Henan Cancer HospitalOTHER_GOV | 0 | Sep 19, 2022 | clinicaltrials |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 100 | Wellmarker BioINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT05544253 | Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC | unknown | Phase 2 / Phase 3 | 68 | West China HospitalOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT04967482 | DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC | unknown | N/A | 216 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05509478 | Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma(LEADER-001) | unknown | Phase 2 | 46 | The First Hospital of Jilin UniversityOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05535647 | Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05519410 | Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 29, 2022 | clinicaltrials |
| NCT05516394 | National Polish Registry of Minimally Invasive Liver Surgery(PL-MILS) | unknown | — | 1,000 | Medical University of WarsawOTHER | 1 | Aug 25, 2022 | clinicaltrials |
| NCT02526043 | Laparoscopic Versus Open Liver Resection for Hepatocellular Carcinoma | unknown | N/A | 180 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04782804 | Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04856761 | A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection | unknown | — | 160 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04974281 | PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC | unknown | Early Phase 1 | 50 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05493332 | HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC | unknown | Phase 2 | 93 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 18, 2022 | clinicaltrials |
| NCT03744624 | Application of 3D Printing in Laparoscopic Surgery of Liver Tumors | unknown | N/A | 85 | Jagiellonian UniversityOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT05059821 | Personalized Cancer Vaccine in Egyptian Cancer Patients(PROVE) | unknown | Phase 1 | 10 | zeinab ahmed yousif hasan ashourOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05488587 | Serum Levels of Some Trace Elements in Hepatocellular Carcinoma Patients | unknown | — | 100 | Sohag UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Dec 7, 2022source: clinicaltrials